Analyzing NeuroPace (NASDAQ:NPCE) and Bionik Laboratories (OTCMKTS:BNKL)

NeuroPace (NASDAQ:NPCE) and Bionik Laboratories (OTCMKTS:BNKL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Institutional & Insider Ownership

78.8% of NeuroPace shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by insiders. Comparatively, 40.4% of Bionik Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares NeuroPace and Bionik Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Bionik Laboratories	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for NeuroPace and Bionik Laboratories, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1	1	4	2	2.88
Bionik Laboratories	0	0	0	0	0.00

NeuroPace currently has a consensus price target of $18.83, suggesting a potential upside of 18.82%. Given NeuroPace’s stronger consensus rating and higher possible upside, equities analysts plainly believe NeuroPace is more favorable than Bionik Laboratories.

Earnings and Valuation

This table compares NeuroPace and Bionik Laboratories”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99 million	5.40	-$21.47 million	($0.65)	-24.38
Bionik Laboratories	N/A	N/A	N/A	($0.38)	N/A

Bionik Laboratories has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Bionik Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

NeuroPace beats Bionik Laboratories on 6 of the 11 factors compared between the two stocks.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

About Bionik Laboratories

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.